The suppliers of the Mantoux in Europe are decreasing. Novartis has announced that it will stop supplying in Italy in a few months. Chiron stopped supplying the UK about 3 years ago. This leaves SSI as almost the only provider for Europe.
There must be a reason for this.
Also, as the market is left to SSI clinicians take the opportunity of the change to look for another methodology, again accelerating the move to IGRAs.
Alex
Add to My Watchlist
What is My Watchlist?
